my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
06-02-2007: Kuros, a biotechnology company that develops novel biologics and biomaterials for localised therapy, announced that it has started a Phase II clinical trial in tibial plateau fractures as part of its collaboration with Baxter in hard and soft tissue repair. The Phase II clinical trial will be conducted by Kuros and aims to evaluate the safety and efficacy of the product.
Kuros' product in this indication utilises Kuros' technology for binding proprietary biologics within Baxter's fibrin-based biomatrix, TISSEEL Fibrin Sealant, to create a bioactive bone graft substitute for in-situ healing of long bone fractures. The product is injected directly at the fracture site, where it forms a solid fibrin composite that matches the shape of the fracture. According to the company, the product promotes bone growth through the release upon cellular demand of a modified version of a naturally occurring bone-forming molecule bound to the fibrin matrix.
Kuros entered into a major licence & collaboration agreement with Baxter Healthcare in 2005. The collaboration covers the development of a number of biological combination products targeted at certain skin and orthopaedic indications.
Watchlist
This is where you can add this news to your personal favourites
Jerini expands collaboration with Baxter to develop non-intraveneous hemophilia therapy
Jerini AG announced the expansion of their current research collaboration with Baxter AG for the development of a non-intravenous therapy for the treatment of hemophilia. The companies have initiated two additional programs aimed at novel targets, potentially offering new therapeutic develo ... more
Kuros starts Phase II clinical trial in bone regeneration
Kuros, a biotechnology company that develops novel biologics and biomaterials for localised therapy, announced that it has started a Phase II clinical trial in tibial plateau fractures as part of its collaboration with Baxter in hard and soft tissue repair. The Phase II clinical trial will ... more
BioVeris Completes Additional Vaccine License
BioVeris Corporation announced that it has entered into a new Technology License Agreement with Baxter Healthcare Corporation. BioVeris received an exclusive, worldwide license to certain patent rights and know-how to use Neisseria meningitidis group Y and Haemophilus influenzae type b (Hib ... more
Baxter ist ein weltweit führender Anbieter von medizintechnischen und pharmazeutischen Produkten. Durch Anwendung und Einsatz neuester Technologien bietet Baxter Hilfe für Maßnahmen, die Leben retten und Leben erhalten. more
Looking for dynamic solutions to power your success? Connect to the resources you need. The stakes in drug development are high. We’ve put together a dynamic portfolio of formulation, packaging, and manufacturing services to support your efforts throughout the development process. At Baxte ... more
Kuros and Synthes Inc. announce license and development agreement
Kuros Biosurgery AG has signed a license and development agreement with Synthes, Inc.. Under the terms of the agreement Synthes and Kuros will work together to commercialize Kuros’ synthetic matrix technology in certain fields.Commenting on today’s announcement, Mr. Didier Cowling, CEO of K ... more
Kuros Biosurgery AG announced that it has received Notice of Allowance for U.S. 11/679,807 from the U.S. Patent Office. The now allowed application acknowledges that Kuros has been first in showing that parathyroid hormone (PTH) when applied locally in a matrix to a bone defect has the abil ... more
KUROS announces allowance of European Patent for synthetic biomaterials
Kuros Biosurgery AG announced the allowance of European Patent Application 00910049 by the European Patent Office. This now allowed patent application is a key component of a broad portfolio of applications and patents designed to protect Kuros’ synthetic biomaterial (matrix) technologies a ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
